Literature DB >> 15347840

Regulation of VEGF-A, VEGFR-I, thrombospondin-1, -2, and -3 expression in a human pituitary cell line (HP75) by TGFbeta1, bFGF, and EGF.

Hidehisa Horiguchi1, Long Jin, Katharina H Ruebel, Bernd W Scheithauer, Ricardo V Lloyd.   

Abstract

Pituitary tumors are highly vascular neoplasms, which suggest an important role of angiogenesis in pituitary tumor growth. We used the human pituitary cell line (HP75) to examine the effects of the growth factors TGFbeta1, bFGF, and EGF on cell growth, and on the regulation of the pro-angiogenic growth factor VEGF-A and the VEGFR-I and the anti-angiogenic molecules thrombospondin (TSP) TSP-1 and TSP-2 along with TSP-3. Real-time RT-PCR was used to measure mRNA levels, and Western blot was used to analyze TSP-1 and TSP-2 protein levels. TGFbeta1 treatment (1 x 10(-9) M) increased VEGF-A mRNA levels significantly (p < 0.05) after 4 and 24 h of treatment. TGF beta1 treatment decreased VEGF-R mRNA levels after 96 h of treatment (p < 0.05). After 96 h of treatment, TSP-1 and TSP-2 mRNA levels were significantly increased (p < 0.05) by TGFbeta1 treatment, which also inhibited HP75 cell growth. Basic FGF also increased TSP-1 mRNA levels after 96 h of treatment, but did not regulate growth of the pituitary tumor cells. Basic FGF and EGF did not modulate changes in VEGF-A mRNA levels after 4 and 24 h of treatment, but EGF increased VEGF-A significantly (p < 0.05) after 96 h of treatment. These results indicate that TGFbeta1 treatment may regulate angiogenesis in pituitary cells by initially increasing levels of pro-angiogenic VEGF-A and then stimulating the anti-angiogenic molecules TSP-1 and TSP-2 levels.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15347840     DOI: 10.1385/ENDO:24:2:141

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  42 in total

Review 1.  Clinical applications of angiogenic growth factors and their inhibitors.

Authors:  N Ferrara; K Alitalo
Journal:  Nat Med       Date:  1999-12       Impact factor: 53.440

Review 2.  Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.

Authors:  D Hanahan; J Folkman
Journal:  Cell       Date:  1996-08-09       Impact factor: 41.582

Review 3.  VEGF: an update on biological and therapeutic aspects.

Authors:  N Ferrara
Journal:  Curr Opin Biotechnol       Date:  2000-12       Impact factor: 9.740

4.  Immunolocalization of vascular endothelial growth factor in the GH3 cell line.

Authors:  S Vidal; M C Oliveira; K Kovacs; B W Scheithauer; R Lloyd
Journal:  Cell Tissue Res       Date:  2000-04       Impact factor: 5.249

5.  Relative abundance of thrombospondin 2 and thrombospondin 3 mRNAs in human tissues.

Authors:  K W Adolph
Journal:  Biochem Biophys Res Commun       Date:  1999-05-19       Impact factor: 3.575

Review 6.  Thrombospondins and tumor angiogenesis.

Authors:  F de Fraipont; A C Nicholson; J J Feige; E G Van Meir
Journal:  Trends Mol Med       Date:  2001-09       Impact factor: 11.951

Review 7.  Angiogenesis in cancer, vascular, rheumatoid and other disease.

Authors:  J Folkman
Journal:  Nat Med       Date:  1995-01       Impact factor: 53.440

8.  Expression of vascular endothelial growth factor in normal pituitary cells and pituitary adenomas producing adrenocorticotropic hormone.

Authors:  T Yamamoto; Y Nishizawa; M Tsuji; Y Saitoh; H Funai; T Hirai; A Sugihara; T Tsujimura; Y Nakata; S Ishiguro; N Terada
Journal:  Endocr Pathol       Date:  1999-06       Impact factor: 3.943

9.  Modulation of transforming growth factor beta receptor levels on microvascular endothelial cells during in vitro angiogenesis.

Authors:  S Sankar; N Mahooti-Brooks; L Bensen; T L McCarthy; M Centrella; J A Madri
Journal:  J Clin Invest       Date:  1996-03-15       Impact factor: 14.808

10.  The structure of human thrombospondin, an adhesive glycoprotein with multiple calcium-binding sites and homologies with several different proteins.

Authors:  J Lawler; R O Hynes
Journal:  J Cell Biol       Date:  1986-11       Impact factor: 10.539

View more
  8 in total

1.  Patterns of gene expression in pituitary carcinomas and adenomas analyzed by high-density oligonucleotide arrays, reverse transcriptase-quantitative PCR, and protein expression.

Authors:  Katharina H Ruebel; Alexey A Leontovich; Long Jin; Gail A Stilling; Heyu Zhang; Xiang Qian; Nobuki Nakamura; Bernd W Scheithauer; Kalman Kovacs; Ricardo V Lloyd
Journal:  Endocrine       Date:  2006-06       Impact factor: 3.633

2.  Purinergic signaling induces thrombospondin-1 expression in astrocytes.

Authors:  Minh D Tran; Joseph T Neary
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-05       Impact factor: 11.205

3.  Heterogeneous activation of the TGFbeta pathway in glioblastomas identified by gene expression-based classification using TGFbeta-responsive genes.

Authors:  Xie L Xu; Ann M Kapoun
Journal:  J Transl Med       Date:  2009-02-03       Impact factor: 5.531

4.  Effects of TGFbeta1 on gene expression in the HP75 human pituitary tumor cell line identified by gene expression profiling.

Authors:  Katharina H Ruebel; Alexey A Leontovich; Yoshinori Tanizaki; Long Jin; Gail A Stilling; Shuya Zhang; Kendra Coonse; Bernd W Scheithauer; Matilde Lombardero; Kalman Kovacs; Ricardo V Lloyd
Journal:  Endocrine       Date:  2008-04-10       Impact factor: 3.633

5.  Pathological Significance and Prognostic Roles of Thrombospondin-3, 4 and 5 in Bladder Cancer.

Authors:  Junki Harada; Yasuyoshi Miyata; Kyohei Araki; Tsuyoshi Matsuda; Yoshiaki Nagashima; Yuta Mukae; Kensuke Mistunari; Tomohiro Matsuo; Kojiro Ohba; Yasushi Mochizuki; Hideki Sakai
Journal:  In Vivo       Date:  2021 May-Jun       Impact factor: 2.155

Review 6.  Thrombospondin-1 as a Paradigm for the Development of Antiangiogenic Agents Endowed with Multiple Mechanisms of Action.

Authors:  Marco Rusnati; Chiara Urbinati; Silvia Bonifacio; Marco Presta; Giulia Taraboletti
Journal:  Pharmaceuticals (Basel)       Date:  2010-04-23

7.  Gremlin, a bone morphogenetic protein antagonist, is a crucial angiogenic factor in pituitary adenoma.

Authors:  Kenta Koketsu; Daizo Yoshida; Kyongsong Kim; Yudo Ishii; Shigeyuki Tahara; Akira Teramoto; Akio Morita
Journal:  Int J Endocrinol       Date:  2015-03-05       Impact factor: 3.257

Review 8.  Molecular Network Basis of Invasive Pituitary Adenoma: A Review.

Authors:  Qi Yang; Xuejun Li
Journal:  Front Endocrinol (Lausanne)       Date:  2019-01-24       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.